Prognosis analysis of patients with mental disorders with COVID-19: a single-center retrospective study

Yan Wan1, Juan Wu2, Lihua Ni3, Qin Qin Luo4, Cheng Yuan5, Fang Fan1, Hong Liu1, Changjiang Zhang6, Yuandi Xiang7, Qin Xie1

1Psychosis Intensive Care Unit, Affiliated Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2Department of Dermatology, Wuhan First Hospital, Wuhan, Hubei, China
3Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
4Department of Traditional Chinese Medicine, Wuhan First Hospital, Wuhan, Hubei, China
5Department of Gynecologic Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
6Department of Cardiology, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Enshi, China
7Department of Otorhinolaryngology, Wuhan First Hospital, Wuhan, Hubei, China

*Equal contribution

Correspondence to: Qin Xie, Yuandi Xiang, Changjiang Zhang; email: 1660449744@qq.com, xiangyuandi@163.com, zcj2008@163.com

Keywords: COVID-19, mental disorder, dementia, inflammatory response

Received: April 19, 2020 Accepted: May 14, 2020 Published: June 19, 2020

Copyright: Wan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Our study aimed to investigate the factors affecting the prognosis of patients with mental disorders with COVID-19. All patients with mental disorders who were diagnosed with COVID-19 at the intensive care unit of Wuhan Mental Health Center during the period January 3 to March 1, 2020 were selected. The influence of the baseline characteristics, clinical symptoms, laboratory parameters and the types of mental disorders on prognosis were analyzed. According to their final prognosis, the patients were divided into the deceased group (5 patients) and the cured group (25 patients). The mortality rate of patients with dementia was significantly higher than that of patients with other mental disorders (P = 0.001). The levels of certain laboratory parameters in the serum of dementia patients were significantly increased compared with levels in nondementia patients (WBC count: 10.100±6.147 vs. 5.694±3.383, p = 0.029; neutrophil count: 8.504±5.993 vs. 3.764±2.733, P = 0.008; BUN: 8.300±4.072 vs. 4.364±1.196, P = 0.001). Our research indicated that the mortality rate of dementia patients with COVID-19 was higher than that of patients with other mental disorders. A focus on the inflammatory response of dementia patients may provide novel ideas for reducing mortality.

INTRODUCTION

An aggressive, acute respiratory disease caused by SARS-CoV-2, a novel coronavirus of zoonotic origin, called COVID-19, has become a new public health crisis threatening the world [1]. Public health and healthcare professionals are at the frontline and work hard to control and mitigate the spread of the pandemic. With the deepening of the understanding of the disease, patients with COVID-19 in various special groups have gradually attracted attention, such as cancer patients [2, 3], end-stage kidney disease patients [4], and pregnant women [5]. Patients with mental disorders need long-term treatment and specialized care, and their health and psychological status are different from those of the general population. The double hit of
mental disorder and COVID-19 in the pandemic has raised great concerns. However, little information about this special group has been reported.

It has been acknowledged that mental disorders are a diverse group of conditions that primarily impair cognition, emotion, and behavioral control. Mental disorders can occur early in life and have a high aggregate prevalence in all countries, especially in low- and middle-income countries. People living with mental disorders have limited access to or difficulties understanding public health information, which predisposes them to an increased chance of infection compared with the general population. Obviously, the double hit of mental disorder and COVID-19 in the pandemic leads to increased danger. Therefore, this study focused on the factors affecting the prognosis of patients with mental disorders (especially dementia) with COVID-19.

RESULTS

The clinical and laboratory parameters of this study are given in Table 1. The cases of a total of 30 patients were reviewed, and patients were divided into the nonsevere symptoms group (n=19) and the severe symptoms group (n=11). There were significant differences in blood oxygen saturation (95.58±1.02% vs. 88.45±3.56%, P < 0.01) and the incidence of certain clinical symptoms (anorexia/nausea, P = 0.02, and dyspnea, P < 0.01) between the nonsevere symptoms group and the severe symptoms group. However, there was no significant difference in baseline data such as age, sex, the type of mental disorder, and heart rate (P > 0.05).

We regrouped the patients according to their final prognosis and divided the patients into the deceased group (n = 5) and the cured group (n = 25). There were significant differences in some clinical symptoms (fatigue, anorexia/nausea and dyspnea) and laboratory parameters (AST and BUN) between the two groups (P < 0.05, Table 2). Surprisingly, the mortality rate of patients with dementia was significantly higher than that of patients with other mental disorders (P = 0.001, Table 2).

To further explain this phenomenon, we compared the blood indexes of dementia patients and nondementia
Table 2. Univariate analysis based on the prognosis of patients.

| Clinical parameters          | Cured(n=25)       | Deceased(n=5)      | ES     | P     |
|-----------------------------|-------------------|--------------------|--------|-------|
| Age (years)                 | 62.72±13.640      | 66.80±5.070        | -0.652 | 0.520 |
| Basic mental illness (n)    |                   |                    |        |       |
| Dementia                    | 2                 | 3                  | 8.112  | 0.004 |
| Nondementia                 | 23                | 2                  |        |       |
| Gender (n)                  |                   |                    |        |       |
| Male/Female                 | 7/18              | 3/2                |        |       |
| Symptom severity (n)        |                   |                    |        |       |
| Severe cases                | 6                 | 5                  | 10.364 | 0.001 |
| Non Severe cases            | 19                | 0                  |        |       |
| Symptom (n)                 |                   |                    |        |       |
| Fever                       | 14                | 5                  | 3.474  | 0.062 |
| Cough                       | 15                | 3                  | 0.000  | 1.000 |
| Muscle soreness             | 1                 | 0                  | 0.207  | 0.649 |
| Expectoration               | 5                 | 0                  | 1.200  | 0.273 |
| Dizziness                   | 2                 | 1                  | 0.667  | 0.414 |
| Diarrhea                    | 6                 | 1                  | 0.037  | 0.847 |
| Fatigue                     | 11                | 5                  | 5.250  | 0.022 |
| Anorexia/Nausea             | 4                 | 3                  | 4.509  | 0.034 |
| Dyspnea                     | 6                 | 5                  | 10.364 | 0.001 |
| Blood routine               |                   |                    |        |       |
| WBC (10^9/L)                | 5.877±3.419       | 9.184±6.720        | -1.633 | 0.107 |
| Neutrophil count (10^9/L)   | 3.978±2.776       | 7.434±6.743        | -1.949 | 0.061 |
| Lymphocyte count (10^9/L)   | 1.393±0.680       | 1.180±0.481        | 0.666  | 0.511 |
| Monocyte count (10^9/L)     | 0.464±0.301       | 0.454±0.106        | 0.075  | 0.941 |
| Hemoglobin (g/L)            | 125.640±15.196    | 131.200±7.050      | -0.793 | 0.435 |
| Platelet count (10^9/L)     | 180.720±49.526    | 143.800±34.172     | 1.582  | 0.125 |
| Albumin (g/L)               | 37.550±5.534      | 34.180±0.838       | 1.199  | 0.241 |
| Blood biochemistry          |                   |                    |        |       |
| AST (U/L)                   | 24.360±12.086     | 49.250±27.585      | -3.157 | 0.004 |
| ALT (U/L)                   | 22.760±13.758     | 31.250±29.296      | -0.971 | 0.340 |
| TBil (umol/L)               | 7.396±3.517       | 7.525±1.611        | -0.071 | 0.944 |
| SCr (umol/L)                | 76.816±43.071     | 111.180±56.265     | -1.552 | 0.132 |
| BUN (mmol/L)                | 4.212±1.613       | 9.060±3.464        | -4.984 | <0.001|
| UA (umol/L)                 | 324.720±97.053    | 351.800±97.513     | -0.569 | 0.574 |

ES=effect size; TBil=total bilirubin; SCr=serum creatinine; BUN=blood urea nitrogen; UA=uric acid

patients. The results showed that certain laboratory parameters in the serum of dementia patients were significantly increased (WBC count: 10.100 ± 6.147 vs. 5.694 ± 3.383, P = 0.029; neutrophil count: 8.504 ± 5.993 vs. 3.764 ± 2.733, P = 0.008; BUN: 8.300 ± 4.072 vs. 4.364 ± 1.196, P = 0.001; Figure 1).

Is there a correlation between the upregulation of inflammation indicators (WBC and neutrophil counts) and the impairment of renal function (BUN)? Our results suggest that WBC and neutrophil counts and BUN levels in nondementia patients were significantly positively correlated (WBC count: r²=0.376, P < 0.05, Figure 2A; neutrophil count: r²=0.325, P < 0.05, Figure 2B). However, we did not find such a significant correlation in patients with dementia (Figure 2C and 2D).

**DISCUSSION**

In this study, we collected data on baseline characteristics, clinical symptoms, laboratory parameters and mental disease types in patients with mental disorders with COVID-19. The above information was used to find internal associations or differences as much as possible. Differences between
Figure 1. Comparison of laboratory parameters between dementia and nondementia patients.
patients with moderate/mild symptoms and patients with severe symptoms were mainly reflected in blood oxygen saturation, anorexia/nausea, and dyspnea. We analyzed the prognosis of patients and found that the mortality rate of dementia patients was significantly higher than that of patients with other mental disorders. In addition, the WBC count, neutrophil count and BUN level of patients with dementia were significantly higher than those of patients with other mental disorders.

Facing such a very interesting result, we needed to explore why the mortality rate of dementia patients was so high. First, dementia tends to have severe mental and behavioral symptoms. Second, due to less activity and long-term bed rest, the incidence of serious complications, such as pressure ulcers, lung infections, and cardiopulmonary insufficiency, is higher in dementia patients than in nondementia patients. Last but not least, inflammation might play an important role in the pathogenesis of dementia [6–8]. Inflammation is a characteristic of Alzheimer’s disease (AD; the most important cause of dementia). AD dementia patients also have different degrees of inflammation [9]. Chronic inflammation is a common feature of various types of vascular dementia (the second most important cause of dementia) [10]. In addition to amyloid protein, inflammatory molecules, including acute inflammatory reactants and inflammatory cytokines, have been found in the cerebrospinal fluid of dementia patients [11]. Peripheral infection will also aggravate the onset and development of AD [12]. However, in another study [13] of general patients with COVID-19, patients with severe cases tended to have higher leukocyte counts and neutrophil-lymphocyte ratios. Therefore, the persistent inflammatory state of dementia patients may be the cause of the increased peripheral blood WBC and neutrophil counts in dementia patients with COVID-19.

At present, there is not enough evidence to support that the renal function damage of dementia patients with COVID-19 is worse than that of patients with other mental disorders. In our study, the inflammatory

![Figure 2. Correlation between inflammation and renal function.](image)
response of patients with mental disorders was associated with renal impairment, but this phenomenon was not statistically significant in patients with dementia. Therefore, the increase in BUN levels may not be unique to patients with dementia with COVID-19. It may be that these patients have severe symptoms, which lead to damage to renal function. Of course, due to the limitation of the sample size of dementia patients, the trend of the correlation analysis may be masked. Therefore, the correlation between the inflammatory response and renal function impairment in dementia patients needs to be treated with caution. At least, based on the current results and previous evidence, it is not enough to deny this conclusion.

It is worth noting that the following limitations of this study cannot be ignored. Since our research is limited to patients with mental disorders, which makes the sample size insufficient, the probability of false-positive errors seen in small-sample clinical studies is difficult to avoid. In addition, dementia may also be accompanied by other mental disorders, and the heterogeneity between patients may result in an overestimation of the statistical results. Nonetheless, our research indicated that the mortality rate of dementia patients with COVID-19 was higher than that of patients with other mental disorders. A focus on the inflammatory response of dementia may provide novel ideas for reducing mortality.

**MATERIALS AND METHODS**

**Participants and materials**

All patients who were diagnosed with mental disorders and with COVID-19 at the intensive care unit of Wuhan Mental Health Center during the period January 2 to March 1, 2020 were selected. The definition of the mental disorders was based on the International Classification of Diseases-10 (ICD-10). The diagnosis of COVID-19 was made according to the standards for the “Diagnosis and Treatment Scheme of New Coronavirus Infected Pneumonia” (trial version 6 [14]). Finally, a total of 30 newly diagnosed COVID-19 patients with mental disorders were considered candidates in our study. Exclusion criteria included other infectious diseases, hepatic or renal insufficiency, and malignancies. No patient received COVID-19-related antiviral or symptomatic treatment before entering this study.

**Data collection**

We reviewed electronic patient records retrospectively; clinical and laboratory parameters were extracted, including sex, age, the types of mental disorders, COVID-19 nucleic acid detection, routine blood test and laboratory biochemical examination results, such as total protein (TP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), blood urea nitrogen (BUN), and uric acid (UA), and so on. These laboratory parameters were evaluated when patients first underwent laboratory tests in the hospital. The study was approved by the Ethics Committee of Wuhan Mental Health Center, and all patients provided informed consent.

**Statistical analysis**

All data were analyzed by using SPSS 16.0 (SPSS Inc., Chicago, IL) and GraphPad Prism 5. Continuous variables are shown as the mean ± the standard deviation (SD), and categorical variables are shown as percentages. Before analysis, the Kolmogorov–Smirnov test was conducted to identify variable normality. Continuous variables with normal distribution were analyzed by an independent-sample t test, and non-normally distributed data were compared by a rank-sum test. P < 0.05 was considered statistically significant.

**Ethical statement**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

**AUTHOR CONTRIBUTIONS**

The work presented here was carried out in collaboration among all authors. YDX, JW and QX defined the research theme and discussed the analyses, interpretation, and presentation. CY and LHN drafted the manuscript, analyzed the data, developed the algorithm and interpreted the results. YW, QQL, CJZ, FF and HL worked together on associated data collection and helped to draft the manuscript. CY and CJZ helped to perform the statistical analysis and reference collection. All authors read and approved the final manuscript.

**CONFLICTS OF INTEREST**

The authors have no conflicts of interest to declare.

**REFERENCES**

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID:31986264

2. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, et al. Clinical characteristics of COVID-19-infected patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020. [Epub ahead of print]. https://doi.org/10.1016/j.anonc.2020.03.296 PMID:32224151

3. Wang Z, Wang J, He J. Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. JAMA Oncol. 2020. [Epub ahead of print]. https://doi.org/10.1001/jamaoncol.2020.1198 PMID:32236504

4. Fu D, Yang B, Xu J, Mao Z, Zhou C, Xue C. COVID-19 infection in a patient with end-stage kidney disease. Nephron. 2020; 144:245–47. https://doi.org/10.1159/000507261 PMID:32222703

5. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020; 395:809–15. https://doi.org/10.1016/S0140-6736(20)30360-3 PMID:32151335

6. Chi GC, Fitzpatrick AL, Sharma M, Jenny NS, Lopez OL, DeKosky ST. Inflammatory biomarkers predict domain-specific cognitive decline in older adults. J Gerontol A Biol Sci Med Sci. 2017; 72:796–803. https://doi.org/10.1093/gerona/glw155 PMID:27522059

7. Zhang LG, Wang LJ, Shen QQ, Wang HF, Zhang Y, Shi CG, Zhang SC, Zhang MY. Paeoniflorin improves regional cerebral blood flow and suppresses inflammatory factors in the hippocampus of rats with vascular dementia. Chin J Integr Med. 2017; 23:696–702. https://doi.org/10.1007/s11655-015-2124-3 PMID:26577108

8. Heringa SM, van den Berg E, Reijmer YD, Nijpels G, Stehouwer CD, Schalkwijk CG, Teerlink T, Scheffer PG, van den Hurk K, Kappelle LJ, Dekker JM, Biessels GJ. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the hoorrn study. Psychoneuroendocrinology. 2014; 40:108–18. https://doi.org/10.1016/j.psyneuen.2013.11.011 PMID:24485482

9. Kulian G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, Volpato S, Atti AR, Blè A, Fellin R. Plasma cytokines profile in older subjects with late onset alzheimer's disease or vascular dementia. J Psychiatr Res. 2007; 41:686–93. https://doi.org/10.1016/j.jpsychires.2006.02.008 PMID:16600299

10. Omoigui S. The interleukin-6 inflammation pathway from cholesterol to aging—role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing. 2007; 4:1. https://doi.org/10.1186/1742-4933-4-1 PMID:17374166

11. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci. 2010; 1207:155–62. https://doi.org/10.1111/j.1749-6632.2010.05726.x PMID:20955439

12. Kamer AR, Craig RG, Dasanayake AP, Brys M, Glodzik-Sobanska L, de Leon MJ. Inflammation and alzheimer’s disease: possible role of periodontal diseases. Alzheimers Dement. 2008; 4:242–50. https://doi.org/10.1016/j.jalz.2007.08.004 PMID:18631974

13. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. [Epub ahead of print]. https://doi.org/10.1093/cid/ciaa248 PMID:32161940

14. Wang SS, Zhou X, Lin XG, Liu YY, Wu JL, Sharifu LM, Hu XL, Rong ZH, Liu W, Luo XP, Chen Z, Zeng WJ, Chen SH, et al. Experience of clinical management for pregnant women and newborns with novel coronavirus pneumonia in tongji hospital, China. Curr Med Sci. 2020; 40:285–89. https://doi.org/10.1007/s11596-020-2174-4 PMID:32219626